Latest Information Update: 03 Oct 2016
At a glance
- Originator Jiangsu Vcare Pharmatech
- Class Small molecules
- Mechanism of Action Platelet ADP receptor antagonists; Platelet aggregation inhibitors; Purinergic P2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute coronary syndromes
Most Recent Events
- 03 Oct 2016 Jiangsu Vcare Pharmatech plans a phase I trial for Acute coronary syndromes in China (ChiCTR-IIR-16009260)
- 19 Mar 2012 Preclinical trials in Acute coronary syndromes in China (PO)